These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 9683774

  • 21. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
    Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K.
    Proc Natl Acad Sci U S A; 1996 Mar 19; 93(6):2398-402. PubMed ID: 8637885
    [Abstract] [Full Text] [Related]

  • 22. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A, Schally AV, Zarandi M, Heinrich E, Groot K, Havt A, Kanashiro CA, Varga JL, Halmos G.
    Prostate; 2007 Sep 01; 67(12):1339-53. PubMed ID: 17624923
    [Abstract] [Full Text] [Related]

  • 23. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
    Kovacs M, Schally AV.
    Proc Natl Acad Sci U S A; 2001 Oct 09; 98(21):12197-202. PubMed ID: 11593037
    [Abstract] [Full Text] [Related]

  • 24. Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.
    Srkalovic G, Schally AV, Wittliff JL, Day TG, Jenison EL.
    Int J Oncol; 1998 Mar 09; 12(3):489-98. PubMed ID: 9472084
    [Abstract] [Full Text] [Related]

  • 25. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K.
    Prostate; 1999 Feb 01; 38(2):151-8. PubMed ID: 9973101
    [Abstract] [Full Text] [Related]

  • 26. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.
    Horvath JE, Bajo AM, Schally AV, Kovacs M, Herbert F, Groot K.
    Proc Natl Acad Sci U S A; 2002 Nov 12; 99(23):15048-53. PubMed ID: 12409615
    [Abstract] [Full Text] [Related]

  • 27. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
    Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T, Brockhoff G, Ortmann O, Diedrich K, Köster F.
    Int J Oncol; 2009 Oct 12; 35(4):789-96. PubMed ID: 19724914
    [Abstract] [Full Text] [Related]

  • 28. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
    Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L.
    Prostate; 2011 May 15; 71(7):736-47. PubMed ID: 20945403
    [Abstract] [Full Text] [Related]

  • 29. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH.
    Kovacs M, Schally AV, Csernus B, Rekasi Z.
    Proc Natl Acad Sci U S A; 2001 Feb 13; 98(4):1829-34. PubMed ID: 11172036
    [Abstract] [Full Text] [Related]

  • 30. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K.
    Breast Cancer Res Treat; 2000 Feb 13; 59(3):255-62. PubMed ID: 10832595
    [Abstract] [Full Text] [Related]

  • 31. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.
    Fekete M, Wittliff JL, Schally AV.
    J Clin Lab Anal; 1989 Feb 13; 3(3):137-47. PubMed ID: 2569034
    [Abstract] [Full Text] [Related]

  • 32. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G, Szende B, Redding TW, Groot K, Schally AV.
    Proc Soc Exp Biol Med; 1989 Dec 13; 192(3):209-18. PubMed ID: 2574866
    [Abstract] [Full Text] [Related]

  • 33. Membrane receptors for peptides in experimental and human pancreatic cancers.
    Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV.
    Pancreas; 1989 Dec 13; 4(5):521-8. PubMed ID: 2573055
    [Abstract] [Full Text] [Related]

  • 34. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G.
    Clin Cancer Res; 2000 Oct 13; 6(10):4158-65. PubMed ID: 11051271
    [Abstract] [Full Text] [Related]

  • 35. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T, Pinski J, Radulovic S, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Mar 01; 91(5):1701-5. PubMed ID: 8127868
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
    Schally AV, Redding TW, Comaru-Schally AM.
    Med Oncol Tumor Pharmacother; 1984 Mar 01; 1(2):109-18. PubMed ID: 6242477
    [Abstract] [Full Text] [Related]

  • 37. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1987 Oct 01; 84(20):7275-9. PubMed ID: 2890164
    [Abstract] [Full Text] [Related]

  • 38. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix.
    Tang X, Yano T, Osuga Y, Matsumi H, Yano N, Xu J, Wada O, Koga K, Kugu K, Tsutsumi O, Schally AV, Taketani Y.
    J Clin Endocrinol Metab; 2002 Aug 01; 87(8):3721-7. PubMed ID: 12161501
    [Abstract] [Full Text] [Related]

  • 39. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
    Rozsa B, Nadji M, Schally AV, Dezso B, Flasko T, Toth G, Mile M, Block NL, Halmos G.
    Prostate; 2011 Apr 01; 71(5):445-52. PubMed ID: 20859992
    [Abstract] [Full Text] [Related]

  • 40. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
    Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K.
    Proc Natl Acad Sci U S A; 2004 Apr 06; 101(14):4996-5001. PubMed ID: 15044692
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.